Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) saw a large drop in short interest in July. As of July 31st, there was short interest totalling 1,890,000 shares, a drop of 6.4% from the July 15th total of 2,020,000 shares. Based on an average daily volume of 381,300 shares, the short-interest ratio is currently 5.0 days. Currently, 2.1% of the shares of the company are sold short.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, August 12th.
Check Out Our Latest Research Report on Compass Therapeutics
Hedge Funds Weigh In On Compass Therapeutics
Compass Therapeutics Trading Down 1.7 %
Shares of NASDAQ:CMPX opened at $1.17 on Wednesday. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.57. The company has a market cap of $160.98 million, a PE ratio of -3.25 and a beta of 0.79. The company’s 50 day moving average is $1.04 and its 200 day moving average is $1.45.
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). The business had revenue of $0.85 million during the quarter. Equities research analysts predict that Compass Therapeutics will post -0.39 earnings per share for the current fiscal year.
Compass Therapeutics Company Profile
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
See Also
- Five stocks we like better than Compass Therapeutics
- What to Know About Investing in Penny Stocks
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- How to Use the MarketBeat Excel Dividend Calculator
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Technology Stocks Explained: Here’s What to Know About Tech
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.